ABBV ▲ +0.3% - AbbVie Inc. $ABBV - AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma AbbVie rose 0.3% following announcement of positive Phase 3 results for etentamig, its experimental multiple myeloma treatment, which demonstrated significant improvements in response rate and progression-free survival in relapsed/refractory patients. The data supports the drug's potential as a new therapeutic option in a major oncology market, though the modest stock movement suggests the market may have partially priced in expectations for the trial outcome. 03-SEP-2026 09:15 AM ET